DIRS.INFO The most relevant business & tech news

☆ Pfizer says no major tornado damage to drug manufacturing areas of North Carolina facility
▼ + stars: | 2023-07-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

In this aerial image, damage is seen to a Pfizer pharmaceutical factory after a tornado hit the facility two days earlier, on July 21, 2023 in Rocky Mount, North Carolina. Pfize r on Friday said there does not appear to be major damage to the drug manufacturing areas of its plant in Rocky Mount, North Carolina, after a tornado hit the facility two days earlier. The North Carolina plant is closed while Pfizer and both local and federal authorities further evaluate the damage. It's one of 10 Pfizer manufacturing sites in the country. Pfizer also noted that it is working closely with Food and Drug Administration Commissioner Robert Califf, North Carolina Gov.

Persons: it's, Robert Califf, Roy Cooper, Califf Organizations: Pfizer, Food and Drug, North Carolina Gov, FDA Locations: Rocky Mount, North Carolina, U.S, North

☆ Shares in Pfizer rivals Hikma, Fresenius rally after tornado hits factory
▼ + stars: | 2023-07-20 | by ( Lucy Raitano | ) www.reuters.com time to read: +1 min

Hikma shares rose by as much as 9.4% in their largest one-day increase since last September. Pfizer is the largest supplier in the U.S. injectables market and Hikma is the second-largest, analysts said. Hikma, which has a market value of around $5.6 billion compared with Pfizer's $205.7 billion, might struggle to meet demand, Herrmann said. European healthcare stocks (.SXDP) were up around 0.7% on the day, outperforming the broader STOXX 600 (.STOXX), which rose 0.4%. Pfizer shares were up 0.16% in premarket trading.

Persons: Fresenius, Max Herrmann, Herrmann, Hikma, Amanda Cooper, Jan Harvey Organizations: Pfizer, Reuters, Thomson Locations: U.S, Rocky Mount, North Carolina, Hikma

☆ Hikma, Fresenius shares rally after tornado hits rival Pfizer's U.S. plant
▼ + stars: | 2023-07-20 | by ( Lucy Raitano | ) www.reuters.com time to read: +2 min

Nearly 25 percent of all sterile injectables used in U.S. hospitals are produced at the Rocky Mount facility, according to Pfizer's website. Hikma shares rose by as much as 9.4% in their largest one-day increase since last September, hitting an 18-month high. Pfizer is the largest supplier in the U.S. injectables market and Hikma is the second-largest, analysts said. Hikma has a market value of around $5.6 billion, compared with Pfizer's $205.7 billion and Fresenius SE's $16.7 billion, according to Refinitiv data. Pfizer shares were up 0.16% in premarket trading.

Persons: Fresenius, Max Herrmann, Herrmann, Hikma, J.P.Morgan, Amanda Cooper, Jan Harvey, Mike Harrison Organizations: Pfizer, Rocky, U.S . Food, Drug Administration, Thomson Locations: U.S, Rocky Mount, North Carolina, Hikma

☆ These cheap stocks pay safe and high dividends
▼ + stars: | 2023-07-19 | by ( John Melloy | ) www.cnbc.com time to read: +1 min

Finding stocks paying high and safe dividend yields is getting harder as recession fears cause companies to hoard cash. With that in mind, CNBC Pro sought to find stocks that are paying high dividends that they can afford. Here was our criteria using data from FactSet: Dividend yield above 4%. Current forward price-earnings ratio is cheaper than its average forward P/E of the last five years. (Forward P/E looks at a share price relative to the consensus earnings estimate for the next 12 months.)

Persons: Dow, drugmaker, Carter's Organizations: Dow Jones, CNBC Pro, drugmaker Pfizer, Pfizer

☆ FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV
▼ + stars: | 2023-07-17 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

The FDA approval of nirsevimab, sold under the brand name Beyfortus, comes ahead of RSV season this fall. This is a major advantage over palivizumab, which is administered monthly throughout RSV season. Nirsevimab is administered either before or during an infant's first RSV season. Toddlers up to two years old who remain vulnerable can also receive the shot during their second RSV season. Pfizer has developed a vaccine that protects infants by administering the shot to the mother while she is pregnant.

Persons: Biden, Nirsevimab Organizations: Drug Administration, AstraZeneca, Sanofi, FDA, Disease Control, Children, CDC, Pfizer Locations: U.S, Nirsevimab

☆ Micron and Pfizer are the most oversold S&P 500 stocks. Here are the other buying opportunities
▼ + stars: | 2023-07-08 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Traders on Wall Street are back to worrying that the Federal Reserve has significantly more ground to cover to tame inflation. CNBC screened the for the most oversold stocks on Wall Street based on their 14-day relative strength index. Chipmaker Micron and pharmaceutical giant Pfizer were among the most oversold stocks on Wall Street with RSI readings of 21.72 and 20.16, respectively. However, the top spot for most overbought stocks currently belongs to AmerisourceBergen , with a 14-day RSI reading of 88.42. ABC YTD mountain AmerisourceBergen is the most overbought stock on Wall Street.

Persons: nonfarm payrolls, FactSet, DAL Organizations: Federal Reserve, CNBC, Chipmaker Micron, Pfizer, Micron, MU, RSI, FactSet, Delta Airlines, ABC Locations: AmerisourceBergen

☆ The options for weight loss treatment are about to explode. These are the companies investors need to know
▼ + stars: | 2023-07-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +14 min

Wegovy was approved as an obesity treatment in June 2021 , but Ozempic, a Type 2 diabetes treatment, has been used off-label for weight loss. Mounjaro uses GLP-1 and gastric inhibitory polypeptide, or GIP, to help patients lose weight. Eli Lilly's oral drug, orforglipron, has an even better profile . They also could be helpful in assisting patients in maintaining weight loss after they've used the injectable versions, he said. Some have highlighted that oral drugs also may be more manageable for patients who can't handle the idea of giving themselves a once-a-week injection.

Persons: Eli Lilly, we're, Jonathan Wolleben, Wegovy, Lilly's tirzepatide, It's, Mounjaro, Wolleben, Eli Lilly's tirzepatide, Lilly, —, Novo, Eli, it's, they've, FactSet, Altimmune's pemvidutide, Morgan Stanley, Mark Purcell, Purcell, Graig Suvannavejh, Suvannavejh, Roth, Dylan Dupuis, Dupuis, Trung Huynh, Goldman Sachs, Chris Shibutani, Shibutani Organizations: Novo Nordisk, JMP Securities, Citizens Company, Nordisk's Ozempic, Food and Drug Administration, Nordisk, Novo, Zealand Pharma, Shandong Suncadia, GSBR, Biosciences, Fujian Shengdi Pharmaceutical, Mizuho Securities, Terns Pharmaceuticals, American Diabetes Association, Viking Therapeutics, Pfizer, Credit Suisse, AstraZeneca, Therapeutics, Medicare, Medicaid, CNBC Pro's Locations: Danish, Shandong, Fujian, Viking

☆ Former Pfizer employee charged with Covid drug insider trading
▼ + stars: | 2023-06-29 | by ( ) edition.cnn.com time to read: +1 min

CNN —The US Securities and Exchange Commission on Thursday charged a former Pfizer employee and his friend for trading on insider information regarding the success of the company’s trial for Paxlovid, its Covid antiviral drug. The US Attorney’s Office of the Southern District of New York also charged Amit Dagar, the former Pfizer employee, and his friend Atul Bhiwapurkar, in a separate case. “The charges in this case relate to the personal conduct of a former Pfizer employee in violation of the company’s policies. Shares of Pfizer rose nearly 11% on November 5, 2021, the day the company announced the results of the Paxlovid trial. Bhiwapurkar, 45, of Milpitas, California, has been charged with two counts of securities fraud and one count of conspiracy to commit securities fraud.

Persons: Amit Dagar, Atul Bhiwapurkar, ”, Dagar, Bhiwapurkar Organizations: CNN, US Securities and Exchange Commission, Pfizer, Paxlovid, US, Office, Southern, of, ” Pfizer, SEC Locations: of New York, Hillsborough , New Jersey, Milpitas , California

☆ 10 things to watch in the stock market Thursday, including bank stress tests and a possible chip trough
▼ + stars: | 2023-06-29 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

U.S. banks go 23 for 23, passing this year's Fed's stress test, including Club names Wells Fargo (WFC) and Morgan Stanley (MS). KeyBanc downgrades Club name Disney (DIS) to sector weight from overweight (hold from buy) without a price target. Piper upgrades to neutral from underweight (hold from sell), Bank of America increases price target to $76 per share from $68. Piper Sandler initiates coverage on the off-price retailers, starting Club holding TJX Companies (TJX) with a buy-equivalent overweight rating and a $110-per-share price target. Cuts price target to $40 per share from $47.

Persons: Premarket, Wells, Morgan Stanley, KeyBanc, Sanjay Mehrotra, McCormick, Piper Sandler, Piper, Eli Lilly, Warren Buffett's Berkshire, Jim Cramer's, Jim Cramer, Jim Organizations: Dow, Nasdaq, Citi, Disney, Micron, Bank of America, Netflix, TJX Companies, Marshalls, Ross Stores, Burlington Stores, Pfizer, Credit Suisse, Occidental Petroleum, Warren, Warren Buffett's Berkshire Hathaway, Berkshire, Energy, Halliburton, HAL, JPMorgan, Jim Cramer's Charitable, CNBC Locations: Big, Maxx, HomeGoods

☆ Credit Suisse downgrades Pfizer, says pharma giant will struggle to keep up with competitors
▼ + stars: | 2023-06-29 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Pfizer 's underperformance could be here to stay, Credit Suisse warned. Analyst Trung Huynh downgraded the pharmaceutical stock to neutral from outperform and cut his price target by $7 to $40. Pfizer said it still has other plans for focusing on obesity, which has been a closely followed area in the pharmaceutical development world. Pfizer has been his worst performing call since the outperform rating at the end of November, with shares underperforming major pharmaceutical peers in the U.S. by 26%. He said concerns that have weighed on the stock include over-optimism on Covid vaccination and booster rates, "ambiguous" guidance on the drug pipeline and negative events for projects in the drug pipeline.

Persons: Trung Huynh, Huynh, CNBC's Michael Bloom Organizations: Pfizer, Credit Suisse Locations: U.S, Covid

☆ Eli Lilly gorges on obesity options
▼ + stars: | 2023-06-27 | by ( ) www.reuters.com time to read: +2 min

NEW YORK, June 27 (Reuters Breakingviews) - Eli Lilly (LLY.N) has filled its plate with potential obesity treatments, unveiling data from two more on Monday. With so many options under development at Lilly, Novo Nordisk (NOVOb.CO) and others, it raises reasonable questions about capital allocation. Obesity drugs have investors salivating, but is this just more pharmaceutical R&D overkill? Pfizer’s cholesterol-lowering Lipitor, for one, reached consumers after rivals, and a decade after Merck’s version. Lilly’s research budget, projected at 24% of revenue this year, exceeds that of many peers, including Pfizer’s (PFE.N) 19%.

Persons: Eli Lilly, Robert Cyran, Aston Martin, Jeffrey Goldfarb, Sharon Lam Organizations: YORK, Reuters, Novo Nordisk, Twitter, Vodafone, Thomson Locations: Lilly, China, Canada

☆ New data fortifies Eli Lilly's standing in the burgeoning market for weight-loss drugs
▼ + stars: | 2023-06-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

Eli Lilly (LLY) bolstered its position in the budding weight-loss drug market after new data showed its oral obesity pill was highly effective in a mid-stage study. Eli Lilly shares are taking a breather Monday, but we see no reason to join the sellers. Eli Lilly funded the trial. Eli Lilly stock is down about 1.3% Monday afternoon, likely on some profit-taking following a solid move up last week. Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Persons: Eli Lilly, LLY, orforglipron, Orforglipron, Eli Lilly's Mounjaro, Mounjaro, Jim Cramer, Lilly's, Geoff Meacham, Meacham, Lilly, It's, we've, Jim Cramer's, Jim, Cristina Arias Organizations: Club, New England, of Medicine, Nordisk, U.S . Food, Drug Administration, Novo Nordisk, Sunday, Bank of America, CNBC, UBS, Pfizer, Company, Pharmaceutical Locations: U.S, Alcobendas, Madrid, Spain

☆ Stocks making the biggest moves midday: Pfizer, Lucid, WSFS Financial and more
▼ + stars: | 2023-06-26 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Lucid Group — Lucid shares jumped 9% after the electric vehicle maker said it will provide powertrain and battery systems to British luxury automaker Aston Martin. Davidson upgraded the stock to buy from neutral, noting WSFS could benefit from a higher-for-longer interest rate environment. UBS upgraded the pharmaceutical stock to buy from neutral, saying the potential for other vaccines for the company isn't fully appreciated by investors. Alphabet — Shares of Alphabet fell 1.8% after UBS downgraded the tech giant to neutral from buy. Tesla — The electric vehicle maker dropped 2.8% after Goldman Sachs downgraded Tesla to neutral from buy.

Persons: Aston, Davidson, WSFS, Tesla, Goldman Sachs, Morgan Stanley, — CNBC's Michelle Fox, Alex Harring, Jesse Pound Organizations: Aston Martin, D.A, Regional Banking, Pfizer, Cruise, Moderna — Moderna, UBS, Barclays Locations: Royal Caribbean

Pfizer CEO Albert Bourla has said an obesity pill could eventually be a $10-billion-a-year product for Pfizer. Truist Securities analyst Robyn Karnauskas said Lilly is now ahead in the race for a once-a-day obesity pill. Pfizer said last month that danuglipron helped patients lose weight on par with Novo Nordisk's (NOVOb.CO) Ozempic in a mid-stage study that tested it in patients with Type 2 diabetes. None of the patients in the lotiglipron trials reported liver-related symptoms or side effects, there was no evidence of liver failure and none required treatment, Pfizer said. Liver enzyme elevations observed in lotiglipron trials have not been seen in patients enrolled in danuglipron trials, the company added.

Persons: Albert Bourla, Eli Lilly, LLY.N, Robyn Karnauskas, Lilly, Pfizer, danuglipron, Manas Mishra, Leroy Leo, Michael Erman, Pooja Desai, Jason Neely, Deepa Babington Organizations: Pfizer Inc, Pfizer, NYSE Arca Pharmaceutical, Truist Securities, Novo Nordisk's, Thomson Locations: United States, Bengaluru, New Jersey

☆ Pfizer to end development of experimental obesity pill due to elevated liver enzymes
▼ + stars: | 2023-06-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer on Monday said it would stop developing its experimental obesity and diabetes pill, lotiglipron, due to elevated liver enzymes in patients who took the drug once a day in mid-stage clinical studies. New York-based Pfizer said it will instead focus on its other oral obesity drug, danuglipron, which is in a fully enrolled phase two clinical trial. Pfizer CEO Albert Bourla has said that an obesity pill could eventually generate $10 billion each year for the company. The new class of obesity drugs is piquing public interest and causing a weight loss industry gold rush. Analysts believe Eli Lilly’s pill has an edge over Pfizer’s danuglipron.

Persons: William Sessa, Albert Bourla, Eli Lilly, Eli Lilly’s, danuglipron, Wells, Mohit Bansal, orforglipron, Bansal Organizations: Pfizer, Novo Nordisk, National Institutes of Health Locations: New York, danuglipron

☆ A Pill Form of Ozempic Is on the Horizon
▼ + stars: | 2023-06-25 | by ( Dani Blum | ) www.nytimes.com time to read: +2 min

Novo Nordisk, the company that manufactures Wegovy and Ozempic, funded both trials. “If you could say, ‘Well, actually, it doesn’t,’ that’s big.”The higher the dose of oral semaglutide, the more side effects seem to come with it. In the trial of people who were overweight or obese, 80 percent of those who took oral semaglutide reported gastrointestinal issues like vomiting, nausea, constipation or diarrhea. Pfizer has also tested its own pill in that drug class. Oral semaglutide is not new: There’s already a tablet form of the compound on the market, sold under the name Rybelsus.

Persons: “, ”, Robert Gabbay, ’, Eli Lilly, Andrew Kraftson Organizations: Novo Nordisk, American Diabetes Association, New England, of Medicine, Pfizer, Drug Administration, Michigan Medicine Locations: Wegovy

☆ Pfizer RSV vaccine for older adults is only slightly less effective after 18 months
▼ + stars: | 2023-06-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Pfizer 's vaccine that protects adults ages 60 and older from respiratory syncytial virus was slightly less effective after 18 months, according to clinical trial results the company announced Wednesday. The data is from New York-based Pfizer's clinical trial on more than 34,000 older adults over two RSV seasons, or 24 months. The vaccine was roughly 49% effective against the same condition with two or more symptoms after 18 months, according to Pfizer. Anderson said studies are ongoing, and so is research evaluating the shot's efficacy in older adults with weak immune systems. RSV kills 6,000 to 10,000 older adults and hospitalizes 60,000 to 160,000 of them every year, according to the CDC.

Persons: Pfizer's, It's, Annaliesa Anderson, Anderson, Pfizer hasn't Organizations: Pfizer, Northern, That's, Centers for Disease Control, and Drug Administration, GlaxoSmithKline, CNBC, CDC Locations: New York, U.S

☆ CDC advisory panel backs use of GSK and Pfizer RSV vaccines in adults 60 and older
▼ + stars: | 2023-06-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The virus is a common respiratory infection that usually causes mild, cold-like symptoms, but more severe cases in older adults and children. Pfizer and GSK on Wednesday both presented new clinical trial data to the panel, which provided a first glimpse of their shots' durability after one RSV season. That's down from more than 85% at the end of the first season in older adults. For less severe RSV disease, efficacy declined to 67.2% over two seasons from 82% after one season. The shots would help the U.S. combat the upcoming RSV season in the fall after an unusually severe RSV season last year.

Persons: Rochelle Walensky, That's, Michael Melgar, Melgar Organizations: Centers for Disease Control, Pfizer, GSK, Food and Drug Administration, CDC, Northern, Seniors Locations: Los Angeles, United States

☆ Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court
▼ + stars: | 2023-06-20 | by ( Spencer Kimball | ) www.cnbc.com time to read: +10 min

And Bristol Myers Squibb is trying protect its blood thinner Eliquis, which brought in $11.8 billion in sales last year, or about 25% of the company's $46 billion total revenue for 2022. Long legal battle aheadMerck, the chamber and Bristol Myers Squibb filed their lawsuits ahead of two key deadlines. Bristol Myers Squibb did not either. If circuit court decisions on the matter contradict one another, the Supreme Court would step in to decide the issue, Bagby said. Bristol Myers Squibb made an identical argument in its complaint.

Persons: Richard A, Gonzalez, Pascal Soriot, Giovanni Caforio, Jennifer Taubert, Johnson, Kenneth C, Frazier, Albert Bourla, Olivier Brandicourt, Win Mcnamee, Drugmaker Merck, Drugmaker, Bristol Myers Squibb, PhRMA, Eli Lilly, Merck, Bristol Myers, Robin Feldman, Nicholas Bagley, Bagley, Gretchen Whitmer, Chris Meekins, Raymond James, Antonin Scalia, Brett Kavanaugh, Neil Gorsuch, Meekins, Long, Xavier Becerra, Randolph Daniel Moss, Barack Obama, Judge Thomas M, Rose, George W, Bush, Kelly Bagby, Bagby, Amgen, Donald Trump, Karine Jean, Pierre, Biden, Jean, we'll, Becerra, Feldman Organizations: Senate, AbbVie Inc, AstraZeneca, Myers Squibb Co, Janssen Pharmaceuticals, Johnson, Merck & Co, Inc, Pfizer, Sanofi, Getty, U.S . Chamber of Commerce, Bristol Myers Squibb, Washington , D.C, Southern, Southern District of, Democratic Party, U.S, Merck, Bristol, Pharmaceutical Research, Manufacturers of America, CNBC, Medicare, University of California College of, Justice Department, Michigan Gov, Bristol Myers, Human Services, Centers, Services, AARP Foundation, HHS, AARP, Specialty Pharmacy, Reuters, Supreme, Appeals, Democratic, U.S . Sixth, Republican, Third, White Locations: America, Washington , DC, Bristol, U.S, Washington ,, Southern District, Southern District of Ohio, New Jersey, Commerce's Dayton , Ohio, San Francisco

☆ Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head start
▼ + stars: | 2023-06-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

But facing pressure to deliver new shots by the fall, Pfizer, Moderna and Novavax began development on versions of their vaccines targeting XBB.1.5 months before the FDA's decision. That doesn't include Johnson & Johnson , a once-leading Covid vaccine developer. Moderna expects a minimum of $5 billion in revenue from its Covid vaccine, its only available product. The cash-strapped company won U.S. approval for its Covid vaccine under emergency use just last year due to regulatory and manufacturing delays. The company hopes to rake in $1.06 billion to $1.24 billion in sales of its Covid vaccine this year.

Persons: Novavax, Dr, Melinda Wharton, Johnson Organizations: Chicago Department of Public Health, Southwest Senior Center, The U.S . Food, Pfizer, Moderna, FDA, Centers for Disease Control, National Center, Manufacturers, U.S, Moderna's Locations: COVID, Chicago , Illinois, The U.S, Novavax, U.S

☆ Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data
▼ + stars: | 2023-06-05 | by ( Julie Steenhuysen | ) www.reuters.com time to read: +5 min

The hope is for "a completely new treatment paradigm in cancer that will be better tolerated and unique to individual patients' tumors," said Dr. Jane Healy, an executive overseeing in early cancer treatment development at Merck. The Merck/Moderna collaboration is one of several combining powerful drugs that unleash the immune system to target cancers with mRNA vaccine technology. Aiming at these unique proteins allows the immune system to kill cancer cells while leaving healthy tissue unscathed. With standard treatment, 90% of pancreatic cancer patients die within five years of diagnosis. The approach first primes the immune system with an older technology called a chimpanzee adenovirus vaccine that targets patients' tumors.

Persons: Andrew Kelly, Keytruda, Jane Healy, Germany's BioNTech, Vinod Balachandran, we've, we're, Andrew Allen, Healy, Julie Steenhuysen, Caroline Humer, Bill Berkrot Organizations: Merck & Co, REUTERS, CHICAGO, Moderna Inc, American Society of Clinical Oncology, Merck, Moderna, Memorial Sloan Kettering Cancer Center, Thomson Locations: Kenilworth , New Jersey, U.S, Chicago, New York, Nature

We are selling 50 shares of Eli Lilly (LLY) at roughly $442 each. Following Monday's trade, Jim Cramer's Charitable Trust will own 150 shares of LLY, decreasing its weighting in the portfolio to about 2.5% from 3.33%. We're taking some Eli Lilly off the table Monday afternoon on the stock's breakout to another new all-time high. The FDA in early January granted accelerated approval to a drug similar to donanemab, which was developed by Japanese pharmaceutical firm Eisai and U.S.-based partner Biogen (BIIB). Like Pfizer's drug, Lilly is working on an oral type-2 diabetes and chronic weight management drug called orforglipron, which could be similar to the Mounjaro injectable.

☆ Here’s what Pfizer and Moderna say is next for their Covid vaccines
▼ + stars: | 2023-05-22 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +9 min

Scott Olson | Getty ImagesThree years and billions of Covid vaccinations into the pandemic, Pfizer and Moderna say their work is far from over. Here's what Moderna and Pfizer say is next for their Covid shots. Annual Covid shotsPfizer and Moderna aim to keep up with a shift in the U.S. toward annual Covid shots rather than frequent booster doses. Miller, who helped lead the development of Moderna's Covid shot in 2020, said the advantages of using mRNA became evident earlier on in the pandemic. 'Next-generation' Covid shotsPfizer's and Moderna's Covid vaccines both deliver robust protection against the virus, but that immunity can start to fade after four to six months.

☆ TipRanks reveals the top 10 health care sector analysts of the past decade
▼ + stars: | 2023-05-21 | by ( Tipranks.Com Staff | ) www.cnbc.com time to read: +5 min

TipRanks leveraged its Experts Center tool to recognize the ones with a high success rate. We also analyzed each stock recommendation made by health care sector analysts in the past decade. TipRanks' algorithms calculated the statistical significance of each rating, average return and the analysts' overall success rate. The buy recommendation generated a return of 397.9% from May 12, 2020 to May 12, 2021. Boris Peaker - TD CowenBoris Peaker has the 10th spot on the list, with a success rate of 47%.

☆ A secretive annual meeting attended by the world's elite has A.I. top of the agenda
▼ + stars: | 2023-05-18 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Sam Altman, CEO of OpenAI, is one among a number of business and political leaders set to join the annual Bilderberg Meeting in Lisbon, Portugal. OpenAI CEO Sam Altman will join forces with key leadership from firms like Microsoft and Google this week as a secretive meeting of the business and political elite kickstarts in Lisbon, Portugal. Artificial intelligence will top the agenda as the ChatGPT chief meets with Microsoft CEO Satya Nadella, DeepMind head Demis Hassabis, and former Google CEO Eric Schmidt at the annual Bilderberg meeting. All in, around 130 participants from 23 countries are set to attend the private meeting — a similar number to previous years. However, the event's organizers say that the discrete nature of the event is to allow for greater freedom of discussion.

Search resuls for: ". Pfizer"

25 mentions found